Polycystic
ovary syndrome or also known as PCOS is one of the most common hormone
disorders affecting women, with a prevalence of 5–10% in women of reproductive
age. Polycystic ovarian syndrome symptomsand treatment are very
common and the reason for it is
androgen excess in women and the most common cause of ovulatory failure we most
commonly seen. Moreover, the androgen excess presents as hirsutism and acne,
whereas an ovulation presents as subfertility and menstrual irregularity takes
place. In addition, PCOS is also associated with obesity. It is therefore
perhaps not surprising that women with PCOS experience mood dysfunction and
psychiatric problems to a greater degree than women without PCOS in their life
as we see on a daily basis. We have also found out that anxiety and
depression are higher in PCOS than any other healthy women. Most of the time we
have found that in depression and anxiety in PCOS is also an important issue
that should be treated.
We suggested
that most mood problems in PCOS are caused by the distress associated with the
symptoms often seen in PCOS. In general, we find that obesity is related to
depression, both in healthy women and in PCOS. In a review of the quality of
life literature on polycystic
ovarian syndrome, depression found
that weight problems had the greatest negative impact on women. However, not
all studies of obesity in PCOS have found this find that depression is higher
in women with PCOS even after controlling for BMI in them.
Per
women vary in how much their mood is affected by the various PCOS symptoms. We
suggest that PCOS symptoms that affect appearance are more likely to cause
distress in younger women than older women. Because PCOS involves so many
potentially distressing symptoms, it is difficult to identify the main cause of
distress or the relative contribution of causal factors. We have noticed that
physical symptoms of PCOS are largely the result of elevated testosterone; for
example, hirsutism is caused by elevated androgen levels. Hirsutism is also
associated with distress in women with PCOS. Thus, it is tempting to view
distress in PCOS as mainly an indirect effect of testosterone and the cure for
distress, therefore, to lower testosterone levels.
Two
drugs widely used to treat the symptoms of PCOS, metformin and the oral
contraceptive co-cyprindiol, differ in their action; metformin acts primarily
to increase insulin sensitivity, whereas co-cyprindiol is composed of estrogen
and anti-androgen. Some authors use the umbrella term ‘anti-androgens’ to
describe these and other medications of this kind used to treat PCOS. In women
with PCOS found that co-cyprindiol was more effective than metformin in
treating acne, whereas hirsutism responded better to metformin than
co-cyprindiol.
We
suggest that the drugs commonly used to reduce symptoms of PCOS may also reduce
the distress associated with these symptoms. In support of this suggestion
found that women with PCOS taking oral contraceptives were significantly less depressed
than those with PCOS not taking oral contraceptives. We have found that
rates of depression were slightly higher in women with PCOS taking
anti-androgens (71%) than women with PCOS not taking anti-androgens (67%).
Depression rates were lower in controls and showed the opposite pattern; 30%
taking anti-androgens and 37% not taking anti-androgens showed some of the sign
of depression. Thus there is, at present, uncertainty regarding the benefits of
medications on mood in PCOS anddepression and anxiety.
The
primary objective of the present paper is to assess the degree to which women
with PCOS score differently to women without PCOS on measures of anxiety and
depression. The secondary objective is to determine whether there is an impact
of BMI and PCOS medication use on anxiety and depression scores rate. All
between-groups designs were considered.
No comments:
Post a Comment